TGIA
CADL icon

Torrey Growth & Income Advisors’s Candel Therapeutics CADL Stock Holding History

Torrey Growth & Income Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740K Sell
66,456
-692
-1% -$5.23K 0.25% 55
2026
Q1 		$318K Buy
67,148
+398
+0.6% +$2.17K 0.13% 85
2025
Q4 		$377K Buy
+66,750
New +$359K 0.13% 74

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Torrey Growth & Income Advisors's CADL Position: Q2 2026 in Review

Torrey Growth & Income Advisors reduced its Candel Therapeutics (CADL) stake by 1% in Q2 2026, selling an estimated $5.23K and leaving 66,456 shares worth $740K. The position accounts for 0.25% of the portfolio, ranked #55.

Torrey Growth & Income Advisors first reported a position in CADL in Q4 2025 and has held it in 3 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Torrey Growth & Income Advisors held 66,456 shares of Candel Therapeutics worth $740K as of Q2 2026.
  • Torrey Growth & Income Advisors sold 692 Candel Therapeutics shares in Q2 2026, an estimated $5.23K.
  • Candel Therapeutics made up 0.25% of Torrey Growth & Income Advisors's portfolio in Q2 2026, its #55 holding.
  • Torrey Growth & Income Advisors first reported a position in Candel Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Torrey Growth & Income Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.